These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 18213449)

  • 21. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome.
    Druker BJ; Sawyers CL; Kantarjian H; Resta DJ; Reese SF; Ford JM; Capdeville R; Talpaz M
    N Engl J Med; 2001 Apr; 344(14):1038-42. PubMed ID: 11287973
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Protein phosphatase 2A interacts with Chk2 and regulates phosphorylation at Thr-68 after cisplatin treatment of human ovarian cancer cells.
    Liang X; Reed E; Yu JJ
    Int J Mol Med; 2006 May; 17(5):703-8. PubMed ID: 16596250
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Disruption and inactivation of the PP2A complex promotes the proliferation and angiogenesis of hemangioma endothelial cells through activating AKT and ERK.
    Xie F; Bao X; Yu J; Chen W; Wang L; Zhang Z; Xu Q
    Oncotarget; 2015 Sep; 6(28):25660-76. PubMed ID: 26308070
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of herbimycin A, an antagonist of tyrosine kinase, on bcr/abl oncoprotein-associated cell proliferations: abrogative effect on the transformation of murine hematopoietic cells by transfection of a retroviral vector expressing oncoprotein P210bcr/abl and preferential inhibition on Ph1-positive leukemia cell growth.
    Okabe M; Uehara Y; Miyagishima T; Itaya T; Tanaka M; Kuni-Eda Y; Kurosawa M; Miyazaki T
    Blood; 1992 Sep; 80(5):1330-8. PubMed ID: 1515646
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
    Steinberg M
    Clin Ther; 2007 Nov; 29(11):2289-308. PubMed ID: 18158072
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Involvement of protein phosphatase 2A in interferon-alpha-2b-induced apoptosis in K562 human chronic myelogenous leukaemia cells.
    Saydam G; Aydin HH; Sahin F; Selvi N; Oktem G; Terzioglu E; Buyukkececi F; Omay SB
    Leuk Res; 2003 Aug; 27(8):709-17. PubMed ID: 12801529
    [TBL] [Abstract][Full Text] [Related]  

  • 27. PP2A deactivation is a common event in oral cancer and reactivation by FTY720 shows promising therapeutic potential.
    Velmurugan BK; Lee CH; Chiang SL; Hua CH; Chen MC; Lin SH; Yeh KT; Ko YC
    J Cell Physiol; 2018 Feb; 233(2):1300-1311. PubMed ID: 28516459
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Protein phosphatase 2A as a potential target for anticancer therapy.
    Kalev P; Sablina AA
    Anticancer Agents Med Chem; 2011 Jan; 11(1):38-46. PubMed ID: 21288198
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Physiologic functions of PP2A: Lessons from genetically modified mice.
    Reynhout S; Janssens V
    Biochim Biophys Acta Mol Cell Res; 2019 Jan; 1866(1):31-50. PubMed ID: 30030003
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mouse model for probing tumor suppressor activity of protein phosphatase 2A in diverse signaling pathways.
    Walter G; Ruediger R
    Cell Cycle; 2012 Feb; 11(3):451-9. PubMed ID: 22262169
    [TBL] [Abstract][Full Text] [Related]  

  • 31. PP2A inhibition is a common event in colorectal cancer and its restoration using FTY720 shows promising therapeutic potential.
    Cristóbal I; Manso R; Rincón R; Caramés C; Senin C; Borrero A; Martínez-Useros J; Rodriguez M; Zazo S; Aguilera O; Madoz-Gúrpide J; Rojo F; García-Foncillas J
    Mol Cancer Ther; 2014 Apr; 13(4):938-47. PubMed ID: 24448818
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Activation of the Tumor Suppressor PP2A Emerges as a Potential Therapeutic Strategy for Treating Prostate Cancer.
    Cristóbal I; González-Alonso P; Daoud L; Solano E; Torrejón B; Manso R; Madoz-Gúrpide J; Rojo F; García-Foncillas J
    Mar Drugs; 2015 May; 13(6):3276-86. PubMed ID: 26023836
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A novel cAMP-stimulated pathway in protein phosphatase 2A activation.
    Feschenko MS; Stevenson E; Nairn AC; Sweadner KJ
    J Pharmacol Exp Ther; 2002 Jul; 302(1):111-8. PubMed ID: 12065707
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Role of serine/threonine protein phosphatase 2A in cancer.
    Schönthal AH
    Cancer Lett; 2001 Sep; 170(1):1-13. PubMed ID: 11448528
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Activation of protein phosphatase 2A by palmitate inhibits AMP-activated protein kinase.
    Wu Y; Song P; Xu J; Zhang M; Zou MH
    J Biol Chem; 2007 Mar; 282(13):9777-9788. PubMed ID: 17255104
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Deregulation of the protein phosphatase 2A, PP2A in cancer: complexity and therapeutic options.
    Grech G; Baldacchino S; Saliba C; Grixti MP; Gauci R; Petroni V; Fenech AG; Scerri C
    Tumour Biol; 2016 Sep; 37(9):11691-11700. PubMed ID: 27444275
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Expressions of four major protein Ser/Thr phosphatases in human primary leukemic cells.
    Yamamoto M; Suzuki Y; Kihira H; Miwa H; Kita K; Nagao M; Tamura S; Shiku H; Nishikawa M
    Leukemia; 1999 Apr; 13(4):595-600. PubMed ID: 10214867
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pathophysiological significance of N-myc downstream-regulated gene 2 in cancer development through protein phosphatase 2A phosphorylation regulation.
    Morishita K; Nakahata S; Ichikawa T
    Cancer Sci; 2021 Jan; 112(1):22-30. PubMed ID: 33128318
    [TBL] [Abstract][Full Text] [Related]  

  • 39. PP2A inhibition determines poor outcome and doxorubicin resistance in early breast cancer and its activation shows promising therapeutic effects.
    Rincón R; Cristóbal I; Zazo S; Arpí O; Menéndez S; Manso R; Lluch A; Eroles P; Rovira A; Albanell J; García-Foncillas J; Madoz-Gúrpide J; Rojo F
    Oncotarget; 2015 Feb; 6(6):4299-314. PubMed ID: 25726524
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Multiple pathways regulated by the tumor suppressor PP2A in transformation.
    Westermarck J; Hahn WC
    Trends Mol Med; 2008 Apr; 14(4):152-60. PubMed ID: 18329957
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.